OQS
SUPN icon

Occudo Quantitative Strategies’s Supernus Pharmaceuticals SUPN Stock Holding History

Occudo Quantitative Strategies’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,462
Closed -$361K – 861
2025
Q2 		$361K Buy
+11,462
New +$367K 0.04% 422
2024
Q3 		– Sell
-7,700
Closed -$206K – 1005
2024
Q2 		$206K Buy
+7,700
New +$223K 0.04% 596
2024
Q1 		– Sell
-7,400
Closed -$214K – 1021
2023
Q4 		$214K Buy
+7,400
New +$196K 0.03% 633
2023
Q3 		– Sell
-27,334
Closed -$822K – 1296
2023
Q2 		$822K Buy
+27,334
New +$956K 0.09% 392
2023
Q1 		– Sell
-6,685
Closed -$238K – 1189
2022
Q4 		$238K Buy
+6,685
New +$232K 0.03% 724
2022
Q1 		– Sell
-22,233
Closed -$648K – 1318
2021
Q4 		$648K Sell
22,233
-1,817
-8% -$55.1K 0.06% 523
2021
Q3 		$641K Buy
+24,050
New +$646K 0.08% 449

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Occudo Quantitative Strategies's SUPN Position: Q3 2025 in Review

Occudo Quantitative Strategies sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 11,462 shares — an estimated $361K sold.

Occudo Quantitative Strategies first reported a position in SUPN in Q3 2021 and held it in 7 quarters. The position peaked at $822K in Q2 2023. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Occudo Quantitative Strategies reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 11,462 Supernus Pharmaceuticals shares in Q3 2025, an estimated $361K.
  • Occudo Quantitative Strategies first reported a position in Supernus Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Occudo Quantitative Strategies's Supernus Pharmaceuticals position peaked at $822K in Q2 2023.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.